DisperSol and Catalent Announce Manufacturing Collaboration
DisperSol and Catalent announce manufacturing collaboration to accelerate DisperSol’s pharmaceutical production.
On August 2, 2021, DisperSol Technologies and Catalent announced a strategic manufacturing collaboration aimed at accelerating the production of various DisperSol pharmaceutical products.
DisperSol’s KinetiSol technology manufacturing line will be installed at Catalent's oral solids development and manufacturing facility in Somerset, NJ. This technology is designed to turn molecules with great clinical promise but poor bioavailability into viable medicine.
Per the agreement, DisperSol will provide the KinetiSol technology while Catalent will provide staff for the development, scale-up, and commercial stages of KinetiSol product creation.
“This strategic collaboration with Catalent is integral to our company as we now move into late clinical-stage development and commercial-scale manufacturing of our products,” said DisperSol CEO Edward M. Rudnic in a press release. “The commercial amorphous solid dispersion manufacturing expertise of Catalent’s team and their globally accredited quality systems make them a perfect partner for DisperSol.”
Source: Catalent
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
